uniQure N.V. (NASDAQ:QURE) Given Consensus Rating of “Moderate Buy” by Analysts

uniQure N.V. (NASDAQ:QURE) has been assigned an average rating of “Moderate Buy” from the thirteen ratings firms that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $60.8182.

QURE has been the topic of a number of recent analyst reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of uniQure in a report on Wednesday, January 14th. Wall Street Zen cut uniQure from a “hold” rating to a “sell” rating in a research note on Sunday, January 11th. The Goldman Sachs Group reduced their price target on shares of uniQure from $56.00 to $38.00 and set a “neutral” rating for the company in a research report on Tuesday, November 4th. Chardan Capital restated a “buy” rating and set a $53.00 price objective on shares of uniQure in a report on Thursday, December 4th. Finally, Mizuho lowered their price objective on shares of uniQure from $60.00 to $33.00 and set an “outperform” rating on the stock in a research report on Monday, December 8th.

Insider Buying and Selling

In other uniQure news, Director Robert Gut sold 25,613 shares of the business’s stock in a transaction on Monday, January 12th. The stock was sold at an average price of $24.62, for a total value of $630,592.06. Following the sale, the director directly owned 32,342 shares in the company, valued at $796,260.04. The trade was a 44.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Jack Kaye sold 6,390 shares of the company’s stock in a transaction on Friday, January 9th. The shares were sold at an average price of $27.28, for a total value of $174,319.20. Following the transaction, the director directly owned 20,439 shares in the company, valued at $557,575.92. This represents a 23.82% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 102,247 shares of company stock worth $2,839,298 in the last ninety days. 4.79% of the stock is currently owned by insiders.

Institutional Investors Weigh In On uniQure

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Assetmark Inc. purchased a new stake in uniQure during the fourth quarter valued at about $445,000. Aberdeen Group plc raised its position in shares of uniQure by 25.1% in the fourth quarter. Aberdeen Group plc now owns 3,678,640 shares of the biotechnology company’s stock valued at $88,030,000 after purchasing an additional 738,897 shares during the period. Hennion & Walsh Asset Management Inc. raised its position in shares of uniQure by 31.2% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 67,739 shares of the biotechnology company’s stock valued at $1,621,000 after purchasing an additional 16,126 shares during the period. SG Americas Securities LLC lifted its stake in shares of uniQure by 508.1% during the 4th quarter. SG Americas Securities LLC now owns 64,326 shares of the biotechnology company’s stock valued at $1,539,000 after buying an additional 53,747 shares in the last quarter. Finally, Assenagon Asset Management S.A. bought a new position in uniQure in the 4th quarter worth approximately $14,524,000. 78.83% of the stock is currently owned by institutional investors.

uniQure Trading Up 10.5%

Shares of QURE stock opened at $25.08 on Monday. uniQure has a 52-week low of $7.76 and a 52-week high of $71.50. The company has a debt-to-equity ratio of 0.23, a quick ratio of 7.12 and a current ratio of 7.12. The company has a 50-day simple moving average of $24.12 and a two-hundred day simple moving average of $28.20. The company has a market capitalization of $1.56 billion, a price-to-earnings ratio of -5.71 and a beta of 0.68.

uniQure (NASDAQ:QURE) last posted its earnings results on Monday, November 10th. The biotechnology company reported ($1.38) EPS for the quarter, missing the consensus estimate of ($0.85) by ($0.53). The firm had revenue of $3.70 million for the quarter, compared to the consensus estimate of $4.46 million. uniQure had a negative return on equity of 373.73% and a negative net margin of 1,492.90%. Research analysts anticipate that uniQure will post -3.75 EPS for the current fiscal year.

About uniQure

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno?associated viral (AAV) vector platform, the company designs single?dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.